---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-213379"
form_type: "8-K"
ticker: "ALMR"
cik: "0002104204"
company_name: "Alamar Biosciences, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:14:53.334535+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Alamar Q1 revenue doubled to $26.0M; net loss $21.3M on convertible note remeasurement

## Summary
- Total revenue $26.0M, +99% YoY; consumable revenue surged 178% to $14.0M.
- Gross margin improved to 56% from 49% on manufacturing efficiencies and product mix.
- Net loss $21.3M, including $8.6M non-cash loss on convertible notes; operating loss $12.3M.
- Cash $69.5M at March 31; after quarter-end IPO raised $197.8M net proceeds.
- Launched NULISAseq Neuro 220 Panel and NULISAqpcr AD 5-plex in Q1.

## SEC filing metadata
- accession: 0001193125-26-213379
- form_type: 8-K
- ticker: ALMR
- cik: 0002104204
- company_name: Alamar Biosciences, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2104204/000119312526213379/0001193125-26-213379-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2104204/000119312526213379/ck0002104204-20260508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-213379
- JSON: https://secwatch.observer/filing/0001193125-26-213379.json
- Plain text: https://secwatch.observer/filing/0001193125-26-213379.txt

## Source-grounded claims
- claim_id: 9797b1efa79dccf3f62cce2978ec35795e780250
  claim: Alamar Biosciences, Inc. reported the quarter ended March 31, 2026 results: revenue $26.0 million, net income $21.3 million.
  evidence_excerpt: Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent Highlights • Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025. • Launched two new products, NULISAseqTM Neuro 220 Panel and
  evidence_url: https://www.sec.gov/Archives/edgar/data/2104204/000119312526213379/0001193125-26-213379-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.